SOX10 Expression Distinguishes Desmoplastic Melanoma From Its Histologic Mimics

Department of Pathology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
The American Journal of dermatopathology (Impact Factor: 1.43). 01/2013; 35(5). DOI: 10.1097/DAD.0b013e31827a0b98
Source: PubMed

ABSTRACT Desmoplastic melanoma (DM) presents diagnostic challenges due to histologic mimics and limited immunohistochemical staining. Although S100 usually stains DM, other melanoma markers (HMB-45 and Melan-A) are often negative. Dermal/subcutaneous mimics of DM [spindle cell/poorly differentiated squamous cell carcinoma, atypical fibroxanthoma (AFX), and sarcoma] show negative or unreliable immunohistochemical staining. Recently, SOX10 expression has been shown to be a sensitive and specific marker of DM. However, there are no published studies comparing the sensitivity and specificity of SOX10 for DM compared with its most common histologic mimics of the dermis/subcutis. We examined 76 cases, including DM (n = 15), spindle cell/poorly differentiated carcinoma (n = 18), AFX (n = 13), sarcoma with spindled morphology (n = 20), and malignant peripheral nerve sheath tumor (MPNST) (n = 10). Most (75%, 15/20) of sarcomas were centered in the dermis/subcutis and included sarcoma not otherwise specified, DFSP with sarcomatous transformation and myxofibrosarcoma. SOX10 was diffusely positive in 100% (15/15) of DMs and showed focal staining in 30% (3/10) of MPNSTs. All other tumors were negative for SOX10 [0% (0/18) of carcinomas, 0% (0/13) of AFXs, 0% (0/20) of sarcomas]. In conclusion, SOX10 is a highly useful marker to confirm the diagnosis of DM. In our study, SOX10 showed 100% sensitivity for DM and SOX10 was negative in all histologic mimics of the dermis/subcutis, including spindle cell carcinoma, AFX and sarcomas. Similar to S-100 protein, some MPNSTs show scattered positivity but did not show diffuse positivity seen in DM.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment of melanoma. While the two drugs shown to improve survival, vemurafenib and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon pre-clinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors, and provides a strategic approach to understand this issue further.Significance. While cSCCs themselves may not be a major clinical problem in the metastatic setting, they are of greater importance as BRAF inhibitors enter adjuvant treatment, particularly as they point to a wider issue of the oncogenic propensity of these drugs. Emerging reports of non-cutaneous malignancies propagated by BRAF inhibitors are of concern, especially as they are thought to be driven by the same process that leads to cSCC. The true relative prevalence of cSCCs with vemurafenib and dabrafenib may inform the relative risk of other non-cutaneous malignancies with these drugs, which should serve to influence clinical management and drug design. This article is protected by copyright. All rights reserved.
    Pigment Cell & Melanoma Research 06/2013; 26(5). DOI:10.1111/pcmr.12132 · 5.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Melanocytes are pigment producing cells which reside in the skin, eyes, ears, heart, and central nervous system meninges of mammals. Schwann cells are glial cells, which closely associate with peripheral nerves, myelinating and sheathing them. Melanocytes and Schwann cells both arise from the neural crest during development and some melanocytes arise directly from Schwann cell precursors lining developing spinal nerves. In this review, we explore the connections between melanocytes and Schwann cells in development and transformation. This article is protected by copyright. All rights reserved.
    Pigment Cell & Melanoma Research 07/2013; 26(5). DOI:10.1111/pcmr.12134 · 5.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Synovial sarcoma and malignant peripheral nerve sheath tumor pose a significant diagnostic challenge given similar histomorphology. The distinction is further complicated by similar immunophenotype and especially by occasional synovial sarcomas that present as intraneural tumors. Although the presence of a t(X;18) rearrangement or expression of TLE1 can help confirm the diagnosis of synovial sarcoma, negative results for these tests are not diagnostic of malignant peripheral nerve sheath tumor. The SOX10 transcription factor, a putative marker of neural crest differentiation, may have diagnostic utility in this differential, but immunohistochemical data are limited. The goal of the present study was to determine the diagnostic utility of SOX10 to discriminate between synovial sarcoma and malignant peripheral nerve sheath tumor. Forty-eight cases of malignant peripheral nerve sheath tumor, all from patients with documented neurofibromatosis, and 97 cases of genetically confirmed synovial sarcoma, including 4 intraneural synovial sarcomas, were immunohistochemically stained for SOX10. The stain was scored for intensity and fraction of cells staining. Thirty-two of 48 malignant peripheral nerve sheath tumors (67%) were SOX10-positive. The majority of malignant peripheral nerve sheath tumors showed ≥2+ staining, but staining did not correlate with grade. By contrast, only 7/97 (7%) synovial sarcomas were SOX10-positive. Only three synovial sarcomas showed ≥2+ staining but, importantly, two of these were intraneural synovial sarcoma. Therefore, SOX10 is a specific (93%), albeit not very sensitive (67%), diagnostic marker to support a diagnosis of malignant peripheral nerve sheath tumor over synovial sarcoma. Furthermore, the stain needs to be interpreted with caution in intraneural tumors in order to avoid a potential diagnostic pitfall. It remains to be determined whether SOX10-positive cells in intraneural synovial sarcoma represent entrapped Schwann cells, synovial sarcoma cells or both.Modern Pathology advance online publication, 9 August 2013; doi:10.1038/modpathol.2013.115.
    Modern Pathology 08/2013; 27. DOI:10.1038/modpathol.2013.115 · 6.36 Impact Factor
Show more